Atypical subtrochanteric and diaphyseal femoral fractures

Second report of a task force of the American society for bone and mineral research

Elizabeth Shane, David Burr, Bo Abrahamsen, Robert A. Adler, Thomas D. Brown, Angela M. Cheung, Felicia Cosman, Jeffrey R. Curtis, Richard Dell, David W. Dempster, Peter R. Ebeling, Thomas A. Einhorn, Harry K. Genant, Piet Geusens, Klaus Klaushofer, Joseph M. Lane, Fergus McKiernan, Ross McKinney, Alvin Ng, Jeri Nieves & 6 others Regis O'Keefe, Socrates Papapoulos, Tet Sen Howe, Marjolein C H Van Der Meulen, Robert S. Weinstein, Michael P. Whyte

Research output: Contribution to journalArticle

607 Citations (Scopus)

Abstract

Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have been reported in patients taking BPs and in patients on denosumab, but they also occur in patients with no exposure to these drugs. In this report, we review studies on the epidemiology, pathogenesis, and medical management of AFFs, published since 2010. This newer evidence suggests that AFFs are stress or insufficiency fractures. The original case definition was revised to highlight radiographic features that distinguish AFFs from ordinary osteoporotic femoral diaphyseal fractures and to provide guidance on the importance of their transverse orientation. The requirement that fractures be noncomminuted was relaxed to include minimal comminution. The periosteal stress reaction at the fracture site was changed from a minor to a major feature. The association with specific diseases and drug exposures was removed from the minor features, because it was considered that these associations should be sought rather than be included in the case definition. Studies with radiographic review consistently report significant associations between AFFs and BP use, although the strength of associations and magnitude of effect vary. Although the relative risk of patients with AFFs taking BPs is high, the absolute risk of AFFs in patients on BPs is low, ranging from 3.2 to 50 cases per 100,000 person-years. However, long-term use may be associated with higher risk (∼100 per 100,000 person-years). BPs localize in areas that are developing stress fractures; suppression of targeted intracortical remodeling at the site of an AFF could impair the processes by which stress fractures normally heal. When BPs are stopped, risk of an AFF may decline. Lower limb geometry and Asian ethnicity may contribute to the risk of AFFs. There is inconsistent evidence that teriparatide may advance healing of AFFs.

Original languageEnglish
Pages (from-to)1-23
Number of pages23
JournalJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Volume29
Issue number1
DOIs
StatePublished - Jan 2014

Fingerprint

Femoral Fractures
Advisory Committees
Femur
Minerals
Bone and Bones
Diphosphonates
Research
Stress Fractures
Teriparatide
Diaphyses
Osteoporotic Fractures
Pharmaceutical Preparations
Lower Extremity
Epidemiology
Spine

Keywords

  • Bisphosphonates
  • Denosumab
  • Fractures
  • Stress Fracture
  • Suppression Of Remodeling

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Atypical subtrochanteric and diaphyseal femoral fractures : Second report of a task force of the American society for bone and mineral research. / Shane, Elizabeth; Burr, David; Abrahamsen, Bo; Adler, Robert A.; Brown, Thomas D.; Cheung, Angela M.; Cosman, Felicia; Curtis, Jeffrey R.; Dell, Richard; Dempster, David W.; Ebeling, Peter R.; Einhorn, Thomas A.; Genant, Harry K.; Geusens, Piet; Klaushofer, Klaus; Lane, Joseph M.; McKiernan, Fergus; McKinney, Ross; Ng, Alvin; Nieves, Jeri; O'Keefe, Regis; Papapoulos, Socrates; Howe, Tet Sen; Van Der Meulen, Marjolein C H; Weinstein, Robert S.; Whyte, Michael P.

In: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, Vol. 29, No. 1, 01.2014, p. 1-23.

Research output: Contribution to journalArticle

Shane, E, Burr, D, Abrahamsen, B, Adler, RA, Brown, TD, Cheung, AM, Cosman, F, Curtis, JR, Dell, R, Dempster, DW, Ebeling, PR, Einhorn, TA, Genant, HK, Geusens, P, Klaushofer, K, Lane, JM, McKiernan, F, McKinney, R, Ng, A, Nieves, J, O'Keefe, R, Papapoulos, S, Howe, TS, Van Der Meulen, MCH, Weinstein, RS & Whyte, MP 2014, 'Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research', Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, vol. 29, no. 1, pp. 1-23. https://doi.org/10.1002/jbmr.1998
Shane, Elizabeth ; Burr, David ; Abrahamsen, Bo ; Adler, Robert A. ; Brown, Thomas D. ; Cheung, Angela M. ; Cosman, Felicia ; Curtis, Jeffrey R. ; Dell, Richard ; Dempster, David W. ; Ebeling, Peter R. ; Einhorn, Thomas A. ; Genant, Harry K. ; Geusens, Piet ; Klaushofer, Klaus ; Lane, Joseph M. ; McKiernan, Fergus ; McKinney, Ross ; Ng, Alvin ; Nieves, Jeri ; O'Keefe, Regis ; Papapoulos, Socrates ; Howe, Tet Sen ; Van Der Meulen, Marjolein C H ; Weinstein, Robert S. ; Whyte, Michael P. / Atypical subtrochanteric and diaphyseal femoral fractures : Second report of a task force of the American society for bone and mineral research. In: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2014 ; Vol. 29, No. 1. pp. 1-23.
@article{0b50cf22a46545899ab7f6199c53cbe5,
title = "Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research",
abstract = "Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have been reported in patients taking BPs and in patients on denosumab, but they also occur in patients with no exposure to these drugs. In this report, we review studies on the epidemiology, pathogenesis, and medical management of AFFs, published since 2010. This newer evidence suggests that AFFs are stress or insufficiency fractures. The original case definition was revised to highlight radiographic features that distinguish AFFs from ordinary osteoporotic femoral diaphyseal fractures and to provide guidance on the importance of their transverse orientation. The requirement that fractures be noncomminuted was relaxed to include minimal comminution. The periosteal stress reaction at the fracture site was changed from a minor to a major feature. The association with specific diseases and drug exposures was removed from the minor features, because it was considered that these associations should be sought rather than be included in the case definition. Studies with radiographic review consistently report significant associations between AFFs and BP use, although the strength of associations and magnitude of effect vary. Although the relative risk of patients with AFFs taking BPs is high, the absolute risk of AFFs in patients on BPs is low, ranging from 3.2 to 50 cases per 100,000 person-years. However, long-term use may be associated with higher risk (∼100 per 100,000 person-years). BPs localize in areas that are developing stress fractures; suppression of targeted intracortical remodeling at the site of an AFF could impair the processes by which stress fractures normally heal. When BPs are stopped, risk of an AFF may decline. Lower limb geometry and Asian ethnicity may contribute to the risk of AFFs. There is inconsistent evidence that teriparatide may advance healing of AFFs.",
keywords = "Bisphosphonates, Denosumab, Fractures, Stress Fracture, Suppression Of Remodeling",
author = "Elizabeth Shane and David Burr and Bo Abrahamsen and Adler, {Robert A.} and Brown, {Thomas D.} and Cheung, {Angela M.} and Felicia Cosman and Curtis, {Jeffrey R.} and Richard Dell and Dempster, {David W.} and Ebeling, {Peter R.} and Einhorn, {Thomas A.} and Genant, {Harry K.} and Piet Geusens and Klaus Klaushofer and Lane, {Joseph M.} and Fergus McKiernan and Ross McKinney and Alvin Ng and Jeri Nieves and Regis O'Keefe and Socrates Papapoulos and Howe, {Tet Sen} and {Van Der Meulen}, {Marjolein C H} and Weinstein, {Robert S.} and Whyte, {Michael P.}",
year = "2014",
month = "1",
doi = "10.1002/jbmr.1998",
language = "English",
volume = "29",
pages = "1--23",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Atypical subtrochanteric and diaphyseal femoral fractures

T2 - Second report of a task force of the American society for bone and mineral research

AU - Shane, Elizabeth

AU - Burr, David

AU - Abrahamsen, Bo

AU - Adler, Robert A.

AU - Brown, Thomas D.

AU - Cheung, Angela M.

AU - Cosman, Felicia

AU - Curtis, Jeffrey R.

AU - Dell, Richard

AU - Dempster, David W.

AU - Ebeling, Peter R.

AU - Einhorn, Thomas A.

AU - Genant, Harry K.

AU - Geusens, Piet

AU - Klaushofer, Klaus

AU - Lane, Joseph M.

AU - McKiernan, Fergus

AU - McKinney, Ross

AU - Ng, Alvin

AU - Nieves, Jeri

AU - O'Keefe, Regis

AU - Papapoulos, Socrates

AU - Howe, Tet Sen

AU - Van Der Meulen, Marjolein C H

AU - Weinstein, Robert S.

AU - Whyte, Michael P.

PY - 2014/1

Y1 - 2014/1

N2 - Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have been reported in patients taking BPs and in patients on denosumab, but they also occur in patients with no exposure to these drugs. In this report, we review studies on the epidemiology, pathogenesis, and medical management of AFFs, published since 2010. This newer evidence suggests that AFFs are stress or insufficiency fractures. The original case definition was revised to highlight radiographic features that distinguish AFFs from ordinary osteoporotic femoral diaphyseal fractures and to provide guidance on the importance of their transverse orientation. The requirement that fractures be noncomminuted was relaxed to include minimal comminution. The periosteal stress reaction at the fracture site was changed from a minor to a major feature. The association with specific diseases and drug exposures was removed from the minor features, because it was considered that these associations should be sought rather than be included in the case definition. Studies with radiographic review consistently report significant associations between AFFs and BP use, although the strength of associations and magnitude of effect vary. Although the relative risk of patients with AFFs taking BPs is high, the absolute risk of AFFs in patients on BPs is low, ranging from 3.2 to 50 cases per 100,000 person-years. However, long-term use may be associated with higher risk (∼100 per 100,000 person-years). BPs localize in areas that are developing stress fractures; suppression of targeted intracortical remodeling at the site of an AFF could impair the processes by which stress fractures normally heal. When BPs are stopped, risk of an AFF may decline. Lower limb geometry and Asian ethnicity may contribute to the risk of AFFs. There is inconsistent evidence that teriparatide may advance healing of AFFs.

AB - Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures. Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur have been reported in patients taking BPs and in patients on denosumab, but they also occur in patients with no exposure to these drugs. In this report, we review studies on the epidemiology, pathogenesis, and medical management of AFFs, published since 2010. This newer evidence suggests that AFFs are stress or insufficiency fractures. The original case definition was revised to highlight radiographic features that distinguish AFFs from ordinary osteoporotic femoral diaphyseal fractures and to provide guidance on the importance of their transverse orientation. The requirement that fractures be noncomminuted was relaxed to include minimal comminution. The periosteal stress reaction at the fracture site was changed from a minor to a major feature. The association with specific diseases and drug exposures was removed from the minor features, because it was considered that these associations should be sought rather than be included in the case definition. Studies with radiographic review consistently report significant associations between AFFs and BP use, although the strength of associations and magnitude of effect vary. Although the relative risk of patients with AFFs taking BPs is high, the absolute risk of AFFs in patients on BPs is low, ranging from 3.2 to 50 cases per 100,000 person-years. However, long-term use may be associated with higher risk (∼100 per 100,000 person-years). BPs localize in areas that are developing stress fractures; suppression of targeted intracortical remodeling at the site of an AFF could impair the processes by which stress fractures normally heal. When BPs are stopped, risk of an AFF may decline. Lower limb geometry and Asian ethnicity may contribute to the risk of AFFs. There is inconsistent evidence that teriparatide may advance healing of AFFs.

KW - Bisphosphonates

KW - Denosumab

KW - Fractures

KW - Stress Fracture

KW - Suppression Of Remodeling

UR - http://www.scopus.com/inward/record.url?scp=84891034178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891034178&partnerID=8YFLogxK

U2 - 10.1002/jbmr.1998

DO - 10.1002/jbmr.1998

M3 - Article

VL - 29

SP - 1

EP - 23

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 1

ER -